In pursuit of its strategy of vertical integration of its flagship healthcare and wellness business, MOHS Analytics has acquired majority ownership of Remed Pharmaceuticals, Inc., a research and development driven company founded in 2002 by pharmaceutical industry pillar Remedios A. Rivera.
Standing from Left to Right: Dr. Kenji M. Asano Jr.(MOHS SVP & Group CFO), Remedios A. Rivera, (Remed Chairman and President), Michael B. Hortaleza(MOHS Chairman and CEO), Jocelyn M. Aberin(Remed VP-Operations)
Remed owns established brands covering products in four different pharmaceutical categories—Vitacare, Respicare, Pediacare and Gastrocare with over 20 brands in its portfolio. These products are distributed through some 4,500 outlets in major national and regional drugstores and pharmacy chains. Remed has grown to leadership position in some of the pharmaceutical categories it is present in, and it is poised to introduce 5 more brands in the coming months.
This acquisition follows MOHS’s purchase in early 2024 of a controlling stake in Zenfro Corporation, a distribution company with a strong and expanding network in South Greater Manila Area handling top food, beverage, home and personal care products.
READ: FDA still evaluating 2 test kits for home use
The acquisitions are in line with MOHS’s 5-year road map to grow into one of the major fully integrated health and wellness companies in the Philippines.
MOHS got a jump start in business by being among the first to bring in affordable test kits and equipment at the start of the COVID-19 pandemic. With the decline of the COVID business, MOHS quickly pivoted to affordable point of care and home test kits for the early detection of diseases such as urinary tract infection, dengue and malaria. From this platform of and experience with affordable health care products, MOHS has diversified into other areas of health care, including healthcare software and technologies, and point of care innovative systems.
Signing from Left to Right: Dr. Kenji M. Asano, Jr.(MOHS SVP & Group CFO), Remedios A. Rivera, (Remed Chairman and President), Michael B. Hortaleza(MOHS Chairman and CEO)
“Vertical integration of our health care business allows MOHS to better control costs to make our products more affordable and our business more sustainable,” says Michael B. Hortaleza, MOHS’s Chairman and CEO. “Our acquisitions this year follow our strategy of engaging in businesses that add value to Philippine society, by making a wide range of affordable health care products accessible to Filipinos nationwide. This is in line with the Philippine Government’s thrust of Universal Health Care and emphasis on primary and preventative health care.”
“Remed’s strategic partnership with MOHS will enable synergies as the strengths of both companies complement each other,” says Remedios A. Rivera, Remed Chairman and President. “Remed can tap MOHS’s distribution expertise in channels it is not currently accessing, while MOHS can tap Remed’s field marketing force to push its health and wellness products to medical professionals. Such a strong partnership will unlock significant growth for Remed both locally and globally.”
“The entry of MOHS into pharmaceuticals through Remed creates synergies from a strategic and financial viewpoint. With our professional operations and automated systems, we have the capability to fully realize these synergies,” says MOHS SVP and Group CFO Dr. Kenji M. Asano, Jr.
For more information on Remed Pharmaceuticals, Inc., you can visit their website at https://remedpharmaph.com/.
ADVT.
This article is brought to you MOHS Analytics Inc.